Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK episode artwork

EPISODE · Nov 7, 2022 · 20 MIN

Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK

from BioCentury This Week · host BioCentury

 BIO needs to pick a leadership team rather than a leader to give the trade group all the skills it needs moving forward, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. Usdin and Editor in Chief Simone Fishburn discuss how BIO needs to address the challenges it now faces, as well as the results of BioCentury’s industry-wide survey on the state of the trade group.BioCentury’s podcast team also assess the latest developments in RSV product development, the infectious disease pipelines of Pfizer and GlaxoSmithKline, and top takeaways from Fishburn’s conversation on The BioCentury Show with Andy Plump, who is president of R&D at Takeda Reach us by sending a text

Episode metadata supplied by the publisher feed · Published Nov 7, 2022

Embed this episode

NOW PLAYING

Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK

0:00 20:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioCentury This Week?

This episode is 20 minutes long.

When was this BioCentury This Week episode published?

This episode was published on November 7, 2022.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!